Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyun | - |
dc.contributor.author | Yang, Bumhee | - |
dc.contributor.author | Nam, Boda | - |
dc.contributor.author | Jeong, Byeong-Ho | - |
dc.contributor.author | Shin, Sumin | - |
dc.contributor.author | Zo, Jae Il | - |
dc.contributor.author | Shim, Young Mog | - |
dc.contributor.author | Kwon, O Jung | - |
dc.contributor.author | Lee, Kyung Soo | - |
dc.contributor.author | Kim, Hojoong | - |
dc.date.accessioned | 2021-07-30T05:12:07Z | - |
dc.date.available | 2021-07-30T05:12:07Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2017-07 | - |
dc.identifier.issn | 0022-5223 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/3509 | - |
dc.description.abstract | Objectives: To evaluate clinical presentations, treatment modalities, and outcomes of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma by stage strata. Methods: We retrospectively reviewed 51 patients diagnosed with pulmonary MALT lymphoma between January 2003 and December 2015. To compare treatment modalities and outcomes, we stratified the patients into low-stage (IE/IIE) and high-stage (IIIE/IVE) groups using modified Ann Arbor staging. Progression-free survival was estimated using Kaplan-Meier curves, and differences were compared using the log-rank test. A hazard ratio of progression by stage strata, adjusted for other clinical variables, was determined using a Cox adjusted proportional hazards model. Results: The majority of patients had stage IE disease (76.5%; 39 of 51). With advancing stage, patients were more likely to have respiratory and B symptoms and higher International Prognostic Index scores. The most common treatment modality was surgical resection in low-stage patients (33 of 43) and chemotherapy in high-stage patients (7 of 8). At a median follow-up of 40.7 months, progressionfree survival was longer for low-stage patients (median, 40.7 months vs 24.9 months; P˂. 001), and high-stage patients were 9.2 times more likely to progress (hazard ratio, 9.24; 95% confidence interval, 1.93-44.36). Among 30 patients with surgically resected stage IE disease, 8 with central lesions were treated via lobectomy and 22 with peripheral lesions were treated via lobectomy (n = 8) or limited resection (n = 14). One of these patients, with a central lesion, experienced disease recurrence. Conclusions: Our findings suggest that the clinical course of low-stage pulmonary MALT lymphoma, for which the mainstay of treatment is surgical resection, might be indolent. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MOSBY-ELSEVIER | - |
dc.title | Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Hyun | - |
dc.identifier.doi | 10.1016/j.jtcvs.2017.03.043 | - |
dc.identifier.scopusid | 2-s2.0-85018172573 | - |
dc.identifier.wosid | 000405374100091 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, v.154, no.1, pp.342 - 349 | - |
dc.relation.isPartOf | JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | - |
dc.citation.title | JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | - |
dc.citation.volume | 154 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 342 | - |
dc.citation.endPage | 349 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | PULMONARY MALT LYMPHOMA | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | TISSUE LYMPHOMA | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | FEATURES | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | extranodal marginal B-cell lymphoma | - |
dc.subject.keywordAuthor | lungm neoplasm | - |
dc.subject.keywordAuthor | treatment outcome | - |
dc.subject.keywordAuthor | pulmonary surgical procedures | - |
dc.subject.keywordAuthor | neoplasm staging | - |
dc.identifier.url | https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0022522317305470?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0022522317305470%3Fshowall%3Dtrue&referrer= | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.